Nonconventional clinical trial designs: Approaches to provide more precise estimates of treatment effects with a smaller sample size, but at a cost

Stroke

Volumn 38, Issue 2 PART 2, 2007, Pages 804-808

  Howard, George ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adaptive trial design; Bayesian statistics; Clinical trials; Frequentist statistics

Indexed keywords

ACCURACY; ALGORITHM; BAYES THEOREM; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DRUG DOSE REGIMEN; METHODOLOGY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANKIN SCALE; SAMPLE SIZE; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

BAYES THEOREM; ENDPOINT DETERMINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 33846562529     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000252679.07927.e5     Document Type: Conference Paper

References (26)

1. Piantadosi S. In: Clinical Trials: A methodologic perspective. Hoboken, NJ: John Wiley & Sons; 2005.
2. Garrett-Mayer E. Understanding the Continual Reassessment Method for dose finding studies: a tutorial. Clinical Trials. 2006;3:57-71.
3. Moller S. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Statist Med. 1995;14:911-922.
4. Piantadosi S, Fisher JD, Grossman S. Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol. 1998;41:429-436.
5. Faries D. Practical modifications of the Continual Reassessment Method for phase I cancer clinical trials. J Biopharm Stat. 1994;4:147-164.
6. Heyd JM, Carlin BP. Adaptive design improvements in the Continual Reassessment Method for phase I studies. Statist Med. 1999:18:1307-1321.
7. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
8. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659-663.
9. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika. 1977;64:153-162.
10. Shih WJ. Group sequential, sample size re-estimation and two-stage adaptive designs in clinical trials: a comparison. Statist Med. 2006;25:933-941.
11. Wittes J, Brittain E. The role of internal pilot studies in increasing the efficiency of clinical trials. Statist Med. 1990;9:65-72.
12. Coffey CS, Muller KE. Controlling test size while gaining the benefits of an internal pilot design. Biometrics. 2001;57:625-631.
13. Gould AL. Interim analyses for monitoring clinical trials that do not materially affect the type I error rate. Statist Med. 1992;11:55-66.
14. Coffey CS, Muller KE. Properties of internal pilots with the univariate approach to repeated measures. Statist Med. 2003;22:2469-2485.
15. Zucker D, Whittes J, Schabenberger O, Brittain E, Proschan M. Internal pilot studies: type I error rate of the naïve t-test. Statist Med. 1999;18:3481-3491.
16. Proschan MA, Hunsbarger SA. Designed extension of studies based on conditional power. Biometrics. 1995;51:1315-1324.
17. Li G, Shih WJ, Xie T, Lu J. A sample size adjustment procedure for clinical trials based on conditional power. Biostatistics. 2002;3:227-287.
18. Muller H, Schafer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. Biometrics. 2001;57:886-891.
19. Li G, Shih WJ, Wang Y. Two-stage adaptive design for clinical trials with survival data. J Biopharm Stat. 2005;15:1-12.
20. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hårdemark HG, Wasiewski WW. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
21. Samsa GP, Reutter RA, Parmigiani G, Ancukiewicz M, Abrahamse P, Lipscomb J, Matchar DB. Performing cost-effectiveness analysis integrating randomized trial data with a comprehensive decision model: application to treatment. J Clin Epidemiol. 1999;52:259-271.
22. Krams M, Lees KR, Berry DA. The past is the future: innovative designs in acute stroke therapy trials. Stroke. 2005;36:1341-1347.
23. Berry DA. Clinical trials: is the Bayesian approach ready for prime time? Yes. Stroke. 2005;36:1621-1622.
24. Howard G, Coffey CS, Cutter GR. Is Bayesian analysis ready for use in Phase III randomized clinical trials? Beware of the sound of the sirens. Stroke. 2005;36:1622-1623.
25. Cui L, Hung HMJ, Wang S. Modification of sample size in group sequential clinical trials. Biometrics. 1999;55:853-857.
26. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics. 1999;55:1286-1290.